Instead of relying only on traditional tissue biopsies, our study showed that a simple blood test could detect and classify advanced breast cancer. Led by Drs. Dave Cescon and Sasha Main @uhn.ca Princess Margaret Cancer Centre: doi.org/10.1158/0008...

Congratulations to Dr. Gilla Shapiro on being named one of the Emerging Leaders in Health Sciences by CAHS! Dr. Shapiro's research in psychosocial oncology, behavioural science, and cancer prevention, has influenced policy, practice, and equitable care in Canada and internationally.

Congratulations to Dr. Amit Oza on receiving 2026 International Gynecologic Cancer Society (IGCS) Lifetime Achievement Award, for his exceptional contributions to gynecologic oncology through research, clinical leadership, mentorship and international collaboration. www.uhn.ca/corporate/ne...

We are proud to host the 2nd Annual Allan Slaight Breakthrough Forum on Cancer Neuroscience, bringing researchers from @pmresearch-uhn.bsky.social @kbi-uhn.bsky.social @camhnews.bsky.social and for the first time, @sickkidsto.bsky.social to explore the exciting frontiers in medicine.

Our new study led by Dr. David Kirsch @uhn.ca @uhnresearch.ca describes an innovative dual recombinase preclinical model of CIC::DUX4 sarcoma, an aggressive cancer affecting young adults, and identifies a promising treatment approach in lab models. doi.org/10.1172/jci2...

New hope for anaplastic thyroid cancer, one of the most aggressive and lethal cancers: our study with @lhsccanada.bsky.social shows combining naporafenib and trametinib effectively shuts down cancer growth in lab models, better than standard therapies: doi.org/10.1016/j.xc... @uhnresearch.ca @uhn.ca

Our researchers developed an artificial intelligence (AI)-based biomarker, called ENLIGHT, that shows promise in predicting immunotherapy benefits across many different cancer types. doi.org/10.1038/s416...; www.marathonofhopecancercentres.ca/impact/news-...

Congratulations to Dr. @bhaibeka.bsky.social on receiving the 2026 inaugural Francis Ouellette Community Award! 🎉 Recognized for his leadership in open science, community building & advancing inclusive, bias-aware AI in computational biology. @uhnresearch.ca @uhn.ca www.linkedin.com/posts/canadi...

Congratulations to our Medical Oncologist & Clinician Investigator Dr. Natasha Leighl on receiving the 2026 Gandara Clinical Research Award from International Society of Liquid Biopsy! This award recognizes outstanding contributions to liquid biopsy research and clinical impact.

Our study shows porphrin-lipid nanoparticles can spot tiny, hidden cancer in the neck more accurately in preclinical models that standard scans often miss, potentially improving how surgeons plan treatment for oral cancer patients. @uhn.ca @uhnresearch.ca www.thno.org/v16p7108.htm

Our new study found that a ctDNA blood test could help identify which patients with early-stage lung cancer (stage I non-small cell lung cancer, NSCLC) are at higher risk of their cancer returning after surgery. doi.org/10.1016/j.jt... @uhnresearch.ca @uhn.ca

Our new study shows that a methylation-based blood test measuring tumour DNA can accurately monitor treatment response & detect signs of treatment failure a median of six months before clinical progression in metastatic breast cancer patients. www.nature.com/articles/s41... @uhn.ca @uhnresearch.ca

Our new study discovered a way to make AML cancer cells behave more normal-like: they differentiate, lose stemness, and become easier to be detected and killed by immune cells—by changing RNA degradation in cancer cell mitochondria. www.nature.com/articles/s41... @uhnresearch.ca @uhn.ca

A new study by @uhn.ca Princess Margaret Cancer Centre and University of Oxford identified a subset of blood stem cells that are shaped by past inflammatory events. These cells can accumulate with age and are linked to mutations with a higher risk of leukemia. www.nature.com/articles/s41...

This month, the 15th Annual Princess Margaret Cancer Centre Research Retreat took place to build collaborations among scientists and clinicians, and to accelerate discoveries that will address patient needs. Congratulations to all our 2026 research award winners! www.linkedin.com/feed/update/...

Our Till & McCulloch Paper of the Year Award in Clinical Research honours the study led by Dr. Jennifer Knox that identified actionable pancreatic tumour mutations—for selecting suitable targeted therapies & chemotherapies in pancreatic cancer cases. pubmed.ncbi.nlm.nih.gov/40929627/

Our Till & McCulloch Paper of the Year award in Translational Research recognizes Dr. Anastasia Tikhonova's study. It identified a new class of T-ALL correlating with a higher risk of poor treatment outcomes. This helps stratify patients & personalize treatments. pubmed.ncbi.nlm.nih.gov/39742502/

Our study found benefits to integrate lung biopsy for patients preparing for allogeneic hematopoietic cell transplantation. Lung biopsy diagnosis altered clinical management for 51% of the cases and led to improved care for patients: pubmed.ncbi.nlm.nih.gov/41992574/ @uhnresearch.ca @uhn.ca

Our new formulation in photothermal therapy achieved complete tumour ablation in vivo. It uses oil-in-water nanoemulsion to reach high-resolution imaging and better light-to-heat conversion rate, for detecting and removing tumours respectively. doi.org/10.1002/anie... @uhnresearch.ca @uhn.ca

Our researchers discover a new marker called ATP2B1 that identifies a rare group of blood stem cells that are especially good at repopulation and self-renewal—offering a new way to study how blood stem cells stay healthy over time. www.pnas.org/doi/10.1073/... @uhn.ca @uhnresearch.ca

Our scientists developed new preclinical models (organoids and PDX) from EBUS needle biopsy samples for studying advanced lung cancer and novel therapeutic research. The models match patient tumours in genetic & pathological features, and treatment response. pubmed.ncbi.nlm.nih.gov/42055160/

Our new study found that ancient DNA sequences in our genome, called transposable elements, can act as control hubs for leukemia stem cells, fueling therapy resistance and relapse in AML. Led by @matlupien.bsky.social & John Dick @uhn.ca @uhnresearch.ca. www.nature.com/articles/s41...

New study introduces MOLEA, an AI platform that designs lipid nanoparticles for precision RNA delivery and therapeutic gene editing. #RNAtherapeutics Read more in Nature Biotech: www.nature.com/articles/s41...

Our researchers have found a new way to generate durable human stem-like memory T cells for cancer immunotherapies—without using conventional methods that restrict their long-term persistence. @pnas.org Read more > www.pnas.org/doi/10.1073/...

Congratulations to Dr. Danielle Rodin on being named Top 20 Under 40 in Canadian Life Sciences! 🎉 As Director of the Global Cancer Program at @pmcancercentre, Dr. Rodin is advancing equitable cancer care worldwide. Read more > top20under40lifesciences.com/2025winners/

Congratulations to our Senior Scientists, Drs. Hansen He and Cheryl Arrowsmith for receiving AACR Scientific Achievement Awards in recognition of their outstanding contributions to cancer research. #AACR26

Congratulations to Dr. George Yousef on his paper being ranked among the top 10 most-cited articles published by the journal Histopathology (@Histo_Journal) in 2024. #TopCitedArticle > onlinelibrary.wiley.com/doi/10.1111/...

Our scientists developed an amino acid–based lipid nanoparticle, inhalable to deliver mRNA medicine into the lung. It has corrected cystic fibrosis mutations in preclinical models, opening routes to treat genetic lung diseases. Led by @BowenLi_Lab @UHN @UofTPharmacy: www.nature.com/articles/s41...

Our recent study found, p53psi, a shortened version of a tumour suppressive protein, can still slow down tumour growth but not enough to fully prevent cancer. It suppresses tumour growth by restricting damaged cells in a state where they can no longer divide: www.pnas.org/doi/10.1073/...

Dr. Farshad Nassiri is using AI and advanced genomic analysis to better predict when meningiomas will return after surgery. His research aims to help doctors tailor treatment decisions and identify new therapeutic opportunities to improve outcomes for patients. www.tfri.ca/our-research...